also that CD40L signaling may modulate cytokine production in disorders associated with impaired type 1 cytokine response.
Before the decline in CD4 cell counts, human immunodeficiency virus (HIV)-infected persons exhibit defects in cell-mediated immunity that include decreased in vitro production of IL-2, IL-12, and IFN-g [10] [11] [12] [13] . Impaired cellular immunity is associated with progression of HIV infection [14, 15] , and worsening of this immune deficiency ultimately contributes to the development of opportunistic infections. The pivotal role of CD40L signaling for regulation of cell-mediated immunity led us to examine whether CD40L induction is defective from the early stages of HIV infection and whether exogenous CD40L reverses impaired IL-12 and IFN-g response in HIV-infected persons.
Subjects, Materials, and Methods

HIV-infected patients and control subjects.
Blood samples were obtained from 110 HIV-infected patients who were followed up at the Infectious Diseases Center at the University of Cincinnati and the Cincinnati Veterans Affairs Medical Center. Patients were grouped according to CD4 cell count status (!200, 200-500, 1500 cells/mL) at the time that blood samples were obtained. Eighteen of the 26 HIV-infected patients with a CD4 cell count 1500 cells/ mL did not have a previously documented CD4 cell count !500 cells/mL. All but 5 patients were treated with combination antiretroviral therapy; 4 of the 5 had a CD4 cell count 1500 cells/mL. Plasma virus load was measured by reverse-transcriptase polymerase chain reaction (Amplicor) at the time of the study. We used 38 HIV-seronegative healthy blood donors (Hoxworth Blood Center, Cincinnati) as control subjects. For studies of in vitro responses to cytomegalovirus (CMV), we used CMV-seropositive subjects. Studies of in vitro reactivity to T. gondii were done, using both T. gondii-seropositive and -seronegative subjects.
Cell preparations and in vitro stimulation with microbial antigens.
Peripheral blood mononuclear cells (PBMC) were obtained, as described elsewhere [16] . T cells, CD4 ϩ T cells, and monocytes were purified by negative depletion, using immunomagnetic beads [8, 16] . For T cell purification, PBMC were incubated with monoclonal antibodies (MAbs) against CD11b (OKM1; American Type Culture Collection [ATCC]), CD16 (Medarex), and CD19 (Coulter-Immunotech). MAbs against CD8 (OKT8; ATCC) and gd T cell receptor (TCR) (anti-TCRd1; gift of M. Brenner, Harvard Medical School, Cambridge) were added to obtain CD4 ϩ T cells. For monocyte purification, PBMC were incubated with MAbs (from Becton Dickinson, except as indicated) against CD2, anti-CD3, anti-CD8, anti-CD19 (Coulter-Immunotech), anti-CD56, anti-CD66b (Coulter-Immunotech), and anti-glycophorin A (10F7; ATCC). Magnetic beads coated with anti-mouse IgG (Dynal) were added to PBMC previously incubated with MAbs. Rosetting cells were removed with a magnet.
These protocols resulted in populations that were either
With the exception of studies of cytokine production in response to CMV, cells were cultured in RPMI 1640 plus 10% T. gondii antibody-negative human AB serum (Gemini Bioproducts). PBMC were incubated with tachyzoites of T. gondii, as reported elsewhere [8] . For the assessment of in vitro responses to CMV, cells were cultured in RPMI 1640 plus 10% CMV antibody-negative fetal bovine serum (HyClone). PBMC from CMV-seropositive persons were incubated with either the AD169 or the VHL/E (gift of J. Waldman, Ohio State University, Columbus) strains of CMV (0.06 pfu/PBMC for studies of IL-12 production; 1 pfu/PBMC for analysis of IFN-g secretion).
To study T cell production of IFN-g, T cells were stimulated with g-irradiated (3000 rad) autologous PBMC that were either uninfected or infected with CMV or T. gondii. Compared with IFN-g secretion in the presence of T cells, g-irradiated infected PBMC, incubated alone or with CD40LT, produced the amount of IFN-17.0% ‫ע‬ 2.0% g present when T cells were added to the wells. Microbial preparations were shown by Limulus amebocyte lysate assay (Sigma Chemical) to be devoid of detectable endotoxin levels (!0.015 endotoxin units/mL). CD40LT (gift of Immunex) was used at 1 mg/mL. Staphylococcus aureus Cowan I strain (SAC; 0.0075%; Calbiochem) was used for the induction of IL-12 secretion. Anti-IL-12 (C8.6; gift of G. Trinchieri, Wistar Institute, Philadelphia), anti-CD40L (M90, gift of Immunex), and isotype control MAbs were used at 10 mg/mL.
Flow cytometry. PBMC were incubated with either anti-CD3 MAb (OKT3; 5 mg/mL; ATCC) or staphylococcal enterotoxin B (SEB; 0.1 mg/mL; Toxin Technology). Thereafter, PBMC were stained with biotinylated anti-CD40L MAb (Ancell) and were incubated with strepavidin phycoerythrin (Ancell), anti-CD4 peridinin chlorophyll protein (Becton Dickinson), either anti-CD69 allophycocyanin (APC) or anti-CD62L APC (PharMingen), and either anti-CD45RA fluorescein isothiocyanate (FITC) or anti-CD45RO FITC MAbs (Coulter-Immunotech). Expression of CD40L, CD45RA, CD45RO, CD62L, and CD69 was analyzed on 10,000 gated CD4 ϩ small lymphocytes. To study binding of anti-CD3 MAb to monocytes, PBMC were incubated with anti-CD3 MAb plus goat anti-mouse (GAM)-FITC (Becton Dickinson) or GAM-FITC alone. Fluorescence on gated monocytes was studied. Cells were fixed in 1% paraformaldehyde and were analyzed by using a FACScalibur analyzer (Becton Dickinson).
Cytokine assays.
Concentrations of IL-12 p40, IL-12 p70 (R&D Systems), and IFN-g (Endogen) were measured by ELISA in supernatants collected at 24 and 72 h, respectively [8, 17] . The lower limit of detection was 39 pg/mL for IL-12 p40 and IFN-g and 0.6 pg/mL for IL-12 p70. Data are shown as the mean of triplicate . wells ‫ע‬ SE Statistical analysis. Groups of HIV-infected patients and control subjects were compared by analysis of variance. We used Student's t test to calculate the significance of the effects of neutralizing MAb.
Results
CD40L restores IL-12 production by PBMC from HIVinfected patients in response to an opportunistic pathogen.
We studied the effects of exogenous CD40L (CD40LT) on cytokine production triggered by the opportunistic pathogens T. gondii and CMV. Naive (CD45RA ϩ ) CD4 ϩ T cells from T. gondiiseronegative adults and newborns proliferate in vitro in response to T. gondii [16] . This reactivity requires antigen processing and is not associated with restriction in TCR Vb usage [16] . Therefore, the model of T. gondii infection allowed us to study not only a recall response (in HIV-infected T. gondiiseropositive patients) but also a presumably primary response (in HIV-infected T. gondii-seronegative patients) against an intracellular pathogen.
To determine whether CD40L modulates IL-12 production in response to an opportunistic pathogen in HIV-infected persons, PBMC from patients and healthy control subjects were incubated with T. gondii in the presence or absence of CD40LT. HIV-infected patients were classified on the basis of their CD4 cell counts (!200, 200-500, and 1500 cells/mL). After incubation with T. gondii, PBMC from the 3 groups of HIV-infected T. gondii-seropositive patients secreted significantly less IL-12 p40 than did those from healthy control subjects ( ; figure P ! .001 1A). Even the 3 patients with a CD4 cell count 1500 cells/mL and undetectable virus loads had IL-12 p40 production below the 10th percentile of that of control subjects. Although CD40LT did not induce IL-12 p40 secretion in the absence of microbial stimulation, the addition of CD40LT to PBMC plus T. gondii significantly enhanced IL-12 p40 production in both control subjects and HIV-infected patients ( ). How-P ! .0001 ever, although CD40LT induced a 6-fold increase in IL-12 production by PBMC from control subjects, production by PBMC from HIV-infected patients was increased 17-38-fold ( figure  1A) . As a result, IL-12 secretion in the presence of CD40LT was no longer significantly different between the HIV-infected and control groups ( ). Similar results were observed with P 1 .1 PBMC from HIV-infected T. gondii-seronegative patients (figure 1B) . Moreover, CD40LT also preferentially enhanced T. gondii-triggered IL-12 p70 production in HIV-infected patients ( figure 1C ). Although parasite-induced IL-12 p70 secretion was significantly lower in HIV-infected persons than in healthy control subjects ( ), there was no significant difference be-P p .01 tween the 2 groups in the presence of CD40LT ( ). Taken P p .4 together, CD40L restored T. gondii-mediated IL-12 production in HIV-infected patients.
We also were interested in learning whether CD40L enhances IL-12 production in response to another opportunistic pathogen, CMV. PBMC from CMV-seropositive HIV-infected patients and healthy control subjects were incubated with CMV (AD169) in the presence or absence of CD40LT. PBMC from control subjects produced variable amounts (often below detectable levels) of IL-12 p40 after incubation with CMV alone ( figure 1D ). Hence, it was not possible to determine whether IL-12 secretion in response to CMV is defective in HIV-infected patients. However, the addition of CD40LT to PBMC plus CMV significantly increased IL-12 p40 production ( ), P ! .0001 causing a 36-fold and a 45-81-fold increase in IL-12 p40 concentrations in healthy control subjects and HIV-infected patients, respectively. Similar results were obtained with a clinical isolate of CMV (VHL/E; data not shown). CD40LT did not induce IL-12 secretion by PBMC incubated in complete medium alone or with a lysate of uninfected human foreskin fibroblasts. In addition, PBMC from healthy CMV-seronegative persons failed to secrete detectable amounts of IL-12 p40 after incubation with the virus plus CD40LT (data not shown). Thus, CD40L also remarkably enhanced IL-12 production in response to CMV in HIV-infected patients.
To determine whether CD40L nonspecifically increases IL-12 production, we examined whether CD40LT modulates IL-12 secretion triggered in a CD40L-independent manner. Bacteria can induce IL-12 production independent of CD40L signaling [8, 18] . Indeed, PBMC from patients with HIGM syndrome exhibit normal IL-12 p40 secretion in response to SAC [8] . Moreover, early IL-12 p40 production (24 h) by PBMC stimulated with SAC is not inhibited by anti-CD40L MAb (control MAb, pg/mL; anti-CD40L MAb, 7876 ‫ע‬ 413 pg/mL; ). Compared with PBMC from con-7672 ‫ע‬ 275 n p 3 trol subjects, PBMC from all 3 groups of HIV-infected patients had impaired production of IL-12 p40 in response to SAC ( ; figure 1E) . In contrast to the results with T. gondii P ! .003 and CMV, CD40LT caused a modest increase (1.2-1.4-fold;
) in IL-12 p40 secretion in all groups. IL-12 p40 pro-P p .04 duction in HIV-infected patients remained significantly lower than that in control subjects ( ). Thus, CD40L has a P ! .02 modest effect on IL-12 production, triggered primarily by CD40L-independent mechanisms.
CD40L restores IFN-g production by PBMC and T cells from HIV-infected patients in response to opportunistic pathogens.
We studied whether CD40L modulates IFN-g production triggered by opportunistic pathogens. PBMC from T. gondiiseropositive subjects were incubated with the parasite with or without CD40LT. In addition, we examined the effects of CD40LT on IFN-g secretion by T cells from CMV-seropositive persons after stimulation with autologous g-irradiated CMV-infected PBMC. IFN-g production in response to T. gondii and CMV was significantly lower in the 3 groups of HIV-infected patients than in the healthy control subjects ( ; figure 2) . P ! .003 Even the 7 patients with a CD4 cell count 1500 cells/mL and undetectable virus loads had IFN-g production that was less than the 10th percentile of that of control subjects. CD40LT did not induce IFN-g secretion in the absence of microbial preparations. In contrast, in the presence of either T. gondii or CMV, CD40LT significantly enhanced IFN-g production in both control subjects 
and HIV-infected patients (
). Although CD40LT induced P ! .004 a 1.4-fold increase in IFN-g production in the control groups, a 4-6-fold increase was observed in the HIV-infected patients (figure 2) . As a result, in the presence of CD40LT and either T. gondii or CMV, PBMC and T cells from HIV-infected patients with a CD4 cell count 1200 cells/mL produced amounts of IFNg similar to those produced by cells from control subjects (P 1 ). Similar results were obtained with T cells and T. gondii-.07 infected PBMC and with PBMC from HIV-infected T. gondiiseronegative patients (data not shown). Thus, CD40L restored IFN-g production in response to opportunistic pathogens in HIV-infected patients with a CD4 cell count 1200 cells/mL.
Then we determined whether the increase in IFN-g synthesis caused by CD40L was mediated through IL-12 production. T cells from HIV-infected patients were stimulated with CMVinfected PBMC with or without CD40LT in the presence of a neutralizing anti-IL-12 MAb. Figure 3 shows that both IFNg production in response to CMV and increased secretion of IFN-g caused by CD40LT were significantly inhibited by anti-IL-12 MAb ( and of inhibi-54.0% ‫ע‬ 5.5%
78.5% ‫ע‬ 1.9% tion, respectively; ; ). Similarly, anti-IL-12 MAb P ! .01 n p 3 significantly impaired the increase in IFN-g secretion caused by addition of CD40LT to PBMC stimulated with T. gondii ( of inhibition; ; ; data not shown). 78.9% ‫ע‬ 6.6% P ! .01 n p 7 Thus, the enhanced production of IFN-g caused by CD40L was mediated mainly through the secretion of bioactive IL-12.
CD40L induction is impaired on CD4 ϩ T cells from early stages of HIV infection. Secretion of human IL-12 triggered by T. gondii is dependent on CD40L signaling [8, 17, 19] . Therefore, the fact that exogenous CD40L restored IL-12 production in response to T. gondii in all groups of HIV-infected patients suggested that CD40L signaling is defective from the early stages of HIV infection. Thus, we studied CD40L expression after TCR/CD3-mediated T cell stimulation.
PBMC from HIV-infected patients and healthy control subjects were incubated with anti-CD3 MAb. Activation of gated CD4 ϩ T cells was determined by CD69 induction, and CD40L expression was analyzed on activated cells. Stimulation with anti-CD3 MAb induced CD40L and CD69 on CD4 ϩ T cells from both healthy control subjects and HIV-infected patients ( figure 4A ). The percentages of CD4 ϩ T cells that became CD69 ϩ were significantly lower in the 3 groups of HIV-infected patients, compared with those in control subjects ( ; fig-P ! .004 ure 4B). However, not all HIV-infected patients exhibited defective CD69 induction. Six of 26 HIV-infected patients had percentages of CD69 ϩ cells greater than the 10th percentile of that of control subjects. In contrast, CD4
ϩ T cells from all HIVinfected patients tested (including those with undetectable virus loads) exhibited impaired CD40L induction after anti-CD3 stimulation (less than the 10th percentile of that of control subjects; figure 4B) ). Of the 8 patients with a CD4 cell 2.1% ‫ע‬ 0.6% P ! .0001 count 1500 cells/mL, 6 did not have previously documented CD4 cell counts below that level.
Defective CD40L induction was not solely due to reduced T cell activation (as assessed by CD69 expression), since decreased CD40L induction was observed even in patients with unimpaired CD69 induction ( figure 4B) 28.2% ‫ע‬ 2.4% n p 12 Finally, lower CD40L induction was not due to impaired FcgRmediated cross-linking of anti-CD3 MAb. As assessed by flow cytometry, the percentages of monocytes that bound anti-CD3 MAb were in HIV-infected patients and 50.9% ‫ע‬ 4.8% in control subjects ( ). Both HIV-infected 19.0% ‫ע‬ 2.3% n p 9 and control subjects had similar mean fluorescence intensity ( vs. , respectively). 955.4 ‫ע‬ 50.3 921.9 ‫ע‬ 46.7 To confirm further that TCR-mediated induction of CD40L is defective in HIV-infected patients, we examined CD40L expression after stimulation with a superantigen. The pattern of CD69 induction in response to SEB was heterogeneous among HIV-infected patients, since 9 of 24 patients had unimpaired induction of CD69. Only the groups of patients with CD4 cell counts !500 cells/mL exhibited significantly lower percentages of CD69 ϩ CD4 ϩ T cells than did the control subjects (P ! ). CD40L induction was impaired in all but 2 of the HIV-.003 infected patients tested (CD4 cell counts, 700 cells/mL and 900 cells/mL; figure 4C ). These 2 patients exhibited defective CD40L induction in response to anti-CD3 MAb ( figure 4B) control group ( ). The lower percentages of 38.5% ‫ע‬ 3.7% CD40L ϩ cells in HIV-infected patients were not caused by differences in kinetics of CD40L induction ( figure 4D ).
CD40L expression was analyzed 6, 10, and 18 h after in vitro stimulation with either anti-CD3 MAb or SEB. In both HIVinfected patients and healthy control subjects, CD40L expression was maximal at 6-10 h, which was followed by marked downregulation at 18 h. Thus, our studies indicate that TCR/CD3-mediated induction of CD40L on CD4 ϩ T cells is defective from the early stages of HIV infection. In addition, this defect is unlikely to be caused exclusively by decreased T cell activation.
Interaction between activated T cells and APCs, in particular B cells, results in CD40-mediated down-regulation of CD40L [20] . Thus, it could be argued that increasing APCs to CD4 ϩ T cell ratios might account for deficient CD40L expression in HIV-infected patients with low CD4 cell counts. To address this possibility, similar numbers of purified CD4
ϩ T cells and monocytes from HIV-infected patients and healthy control subjects were incubated with anti-CD3 MAb. The percentages of CD40L ϩ cells were markedly lower in purified CD4 ϩ T cells from HIV-infected patients than those from control subjects ( and , respectively; ; 10.6% ‫ע‬ 1.8% 32.4% ‫ע‬ 2.0% P p .0002 ; figure 5 ). This defect did not solely reflect impaired T n p 4 cell activation, since, when CD69 ϩ CD4 ϩ T cells were analyzed, and of these cells were CD40L ϩ 83.8% ‫ע‬ 3.5% 38.3% ‫ע‬ 4.4% in the control and HIV-infected groups, respectively. Monocytes from HIV-infected persons exhibit increased CD40 expression [21, 22] . Thus, we assessed whether monocytes from HIV-infected patients mediated impaired CD40L induction. Regardless of the source of monocytes, CD40L induction remained deficient in CD4 ϩ T cells from HIV-infected subjects ( figure 5 ). Collectively, our data indicate that CD4 ϩ T cells from HIVinfected persons are defective in their expression of CD40L during APC-mediated T cell stimulation.
Discussion
Before CD4
ϩ T cell depletion, HIV-infected patients exhibit dysregulated in vitro cytokine production that appears to play a role in progression of HIV infection. One salient feature is impaired IL-12 secretion [10, [23] [24] [25] . Mechanisms proposed to explain defective IL-12 production include HIV infection of IL-12-producing cells, enhanced secretion of IL-10 and/or prostaglandin E 2 , impaired priming by IFN-g, and defective T cell costimulation [10, 21, 23, 24, 26] . However, studies that addressed the potential mechanisms of decreased IL-12 production have reported contrasting results [10, 23, 25] . Therefore, the pathogenesis of diminished IL-12 production in HIV infection remains to be fully understood.
Two previous studies evaluated the effects of CD40L stimulation on IL-12 secretion by PBMC from HIV-infected patients. Although incubation of these cells with CD40LT alone failed to alter IL-12 p70 production in response to SAC, the combination of IFN-g and CD40LT normalized IL-12 p70 secretion [21] . PBMC from HIV-infected patients and healthy control subjects produced comparable amounts of IL-12 p70 after stimulation with CD40L-transfected L cells [27] . However, it is difficult to assess the role of CD40L on APC function from studies that use L cells [28] . These cells secrete colony-stimulating factors that probably act in concert with CD40L to affect monokine production [28] . Taken together, none of these studies demonstrated that CD40L alone normalizes defective in vitro secretion of IL-12 p70 in HIV-infected persons.
Given the central role of CD40L in the regulation of cellmediated immunity, we examined whether defective CD40L signaling could explain impaired type 1 cytokine response in HIV-infected patients. We found that exogenous CD40L alone restored IL-12 p70 production in response to an opportunistic pathogen in HIV-infected patients. This increased IL-12 production, in turn, mediated enhanced IFN-g secretion. In addition, CD4
ϩ T cells from HIV-infected patients, even those with a CD4 cell count 1500 cells/mL, had defective CD40L induction after TCR/CD3 stimulation. Since CD40L regulates IL-12 secretion during primary and recall immune responses [8, 17, 19, [29] [30] [31] , impaired CD40L induction may explain decreased T cell-dependent IL-12 production in HIV infection.
CD40L is required in humans for optimal IL-12 production in response to T. gondii [8, 17, 19] . Thus, our results suggest that impaired CD40L signaling largely causes defective IL-12 secretion in HIV-infected persons during either a recall or primary immune response to an opportunistic pathogen. Given that IL-12 is crucial for the generation and maintenance of protective immunity against opportunistic infections [32, 33] , defective CD40L signaling may contribute to susceptibility to these infections in HIV-infected patients. Indeed, CD40-CD40L interaction is important for in vivo resistance against opportunistic pathogens. Mice deficient of CD40L expression or treated with an anti-CD40L MAb are unable to control infections with Pneumocystis carinii, Cryptosporidium parvum, Mycobacterium avium, and T. gondii [34] [35] [36] [37] . However, it is unclear whether a protective role of CD40L also applies to other pathogens.
CD40L knockout mice infected with M. tuberculosis or Histoplasma capsulatum generate a protective type 1 immune response [38, 39] . With T. gondii infection, CD40L knockout mice develop encephalitis and have decreased in vivo and in vitro production of IL-12; however, in vivo and in vitro secretion of IFN-g are similar to those in wild-type animals [36] . The latter study did not distinguish between T cell and NK cell production of IFNg. In addition, although brain mononuclear cells (BMNC) from CD40L knockout mice exhibit unimpaired IFN-g secretion in response to T. gondii lysate antigens, BMNC from these mice have significantly increased CD4 ϩ T cell percentages, compared with those in control subjects. Thus, it is possible that the higher frequency of CD4 ϩ T cells could alter IFN-g production in response to T. gondii soluble antigens in CD40L knockout mice. Finally, studies in CD40L knockout mice should be interpreted with caution, because these animals can develop compensatory mechanisms of resistance against intracellular pathogens, as indicated by studies of the immune response to Salmonella dublin [40] .
Our demonstration that IL-12 and IFN-g production in response to CMV was modulated by CD40LT suggests that CD40-CD40L interaction may be important for control of CMV. Indeed, mice deficient in CD40 expression exhibit increased susceptibility to murine CMV, and CMV end-organ disease has been reported in patients with HIGM syndrome [7, 41] . Of interest, PBMC from some HIV-infected patients secreted detectable amounts of IL-12 p40 after incubation with CMV. It remains to be determined whether this seemingly unimpaired IL-12 production is caused by a compensatory increase in the frequencies of CMV-specific CD4 ϩ memory T cells in patients with active HIV disease [42] .
Previous reports indicate that the percentage of lymphocytes that become CD40L ϩ after phorbyl myristate acetate/ionomycin stimulation is decreased in HIV-infected persons [43, 44] . However, it has been proposed that this defect is caused simply by a decrease in CD4 ϩ T cells rather than by a specific defect in CD40L expression [43] . Given the importance in humans of CD40L for IL-12 production in response to T. gondii [8, 17, 19] , our demonstration that CD40LT restores T. gondii-induced IL-12 secretion in HIV-infected patients suggests that CD40L signaling is defective in these patients. Indeed, we showed that CD40L induction mediated by TCR/CD3 signals is impaired from the early stages of HIV infection. Although 1 group reported that CD40L induction was markedly reduced in patients with a CD4 cell count !200 cells/mL [22] , the study either used P815 cells as accessory cells instead of human APCs or assessed CD40L expression after 18-72 h of in vitro stimulation. CD40L induction normally occurs after TCR stimulation mediated by APCs and is an early event during APC-T cell interaction [45] . Thus, the time points chosen in our study to examine CD40L expression and the use of human APCs seem more appropriate to assess CD40L induction.
T cells from HIV-infected patients can exhibit defective activation. In this regard, CD69 induction in response to soluble anti-CD2 or bead-bound anti-CD3 MAbs is impaired in CD4 ϩ T cells from these patients [46] . As confirmed by our studies, this abnormality is not detected in all HIV-infected patients, and the prevalence of depressed CD69 induction increases with decreasing CD4 cell counts [46] . In contrast, we demonstrated impaired CD40L induction even in patients with a normal CD69 response. Thus, decreased CD40L induction is a more frequent phenomenon in HIV-infected patients, which argues for the importance of this defect. Although it is likely that impaired CD40L induction is, in part, due to decreased T cell activation, the lack of close association between CD40L and CD69 expression suggests that there are additional mechanisms responsible for impaired CD40L induction in CD4 ϩ T cells from HIV-infected persons.
Although controversial, subpopulations of CD4 ϩ T cells appear to differ in their capacity to express CD40L. Although in some studies TCR/CD3 stimulation induces CD40L primarily on CD45RA ϩ (naive) CD4 ϩ T cells [47] , in others, CD40L induction is either higher in CD45RA Ϫ (memory) CD4 ϩ T cells [48] , or similar in both subsets of CD4 ϩ T cells [49] . Defective CD40L induction was noted on both CD45RA ϩ CD62L ϩ and CD45RO ϩ CD4 ϩ T cells from HIV-infected persons. It remains to be determined whether a more detailed phenotypic analysis would reveal that loss of a particular subpopulation of CD4 ϩ T cells contributes to impaired CD40L induction in HIV-infected patients.
Of potential relevance to the regulation of CD40L induction is the lower expression of CD28 on CD4 ϩ T cells from these subjects [50] . Although CD40L induction appears to be regulated primarily by TCR signals [51] , CD28 stabilizes CD40L expression [52, 53] . However, there is only a modest decrease in CD28 expression on CD4 ϩ T cells from HIV-infected patients [50] , and their response to CD28 costimulation is normal or increased [54] . Although freshly isolated monocytes from HIVinfected patients have reduced expression of CD80 and CD86 (counterreceptors for CD28) [55] , our results argue against these cells being responsible for decreased CD40L induction. Future studies are required to determine whether defective TCR and/ or CD28 signals are involved in the pathogenesis of impaired CD40L induction. Antiretroviral regimens that include protease inhibitors have improved survival of HIV-infected patients. Most persons treated with such regimens experience a marked reduction in plasma viremia and an increase in CD4 cells [56] . However, antiretroviral therapy may not induce full immune reconstitution [57] [58] [59] . Our studies indicate that defective CD40L signaling can offer a basis for decreased T cell-dependent IL-12 production in HIV-infected patients. This work and the demonstration that the level of CD40L expression on CD4 ϩ T cells affects the development of T cell-mediated immunity [60] suggest that impaired CD40L signaling contributes to immunosuppression in HIV infection. Because CD40L induction was defective even in patients receiving antiretroviral therapy, approaches aimed at restoring CD40L signaling may help achieve improved immune reconstitution in HIV-infected persons.
